Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Pollard

Allergy & Immunology Louisville, KY Medical Doctor

NPI 1629077698 CMS profile 119536

9800 Shelbyville Rd, Suite #220, Louisville, KY 40223

Open in the dashboard

General payments

$301,010

461 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$162,066 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Stephen Pollard of Louisville, KY is reported in the CMS Open Payments database as having received $301,010 across 461 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $162,066 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,450 57
2024 General $39,312 54
2023 General $69,905 103
2022 General $42,833 65
2021 General $28,382 42
2020 General $17,807 32
2019 General $76,322 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Pollard
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Stephen Pollard were reported at $26,450. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Stephen Pollard Allergy & Immunology median Middle half National median
2019 $76,322 $594 $163–$1,512 $163
2020 $17,807 $426 $106–$1,233 $114
2021 $28,382 $638 $157–$1,708 $132
2022 $42,833 $790 $205–$1,961 $149
2023 $69,905 $852 $220–$2,147 $160
2024 $39,312 $865 $203–$2,267 $164
2025 $26,450 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $130,734 117 payments
  2. Genzyme Corporation $88,769 65 payments
  3. GlaxoSmithKline, LLC. $67,938 123 payments
  4. Genentech USA, Inc. $4,784 18 payments
  5. BioCryst Pharmaceuticals, Inc. $2,650 8 payments
  6. Incyte Corporation $2,354 3 payments
  7. AstraZeneca Pharmaceuticals LP $1,823 46 payments
  8. CSL Behring $358 13 payments
  9. Amgen Inc. $287 10 payments
  10. OptiNose US, Inc. $164 5 payments
  11. Other $1,148 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $267,735 89 payments
  2. Travel and Lodging $13,148 50 payments
  3. Food and Beverage $11,950 316 payments
  4. Consulting Fee $5,975 2 payments
  5. Honoraria $2,100 1 payment
  6. Education $103 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $113,593 101 payments
  2. DUPIXENT Immunology $78,410 68 payments
  3. NUCALA Immunology $36,139 53 payments
  4. NUCALA Respiratory $31,050 30 payments
  5. DUPIXENT Immunology And Inflammation $6,940 9 payments
  6. Xolair $4,784 18 payments
  7. TEZSPIRE $713 12 payments
  8. TRELEGY ELLIPTA $604 41 payments
  9. FASENRA $476 11 payments
  10. Hizentra $284 9 payments
  11. Other $2,596 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,717

Median for Allergy/ Immunology: 449

Drug cost

$521,741

Median for Allergy/ Immunology: $169,700

Branded share of claims

37.6%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 107 $91,819
Dupixent Syringe Dupilumab Brand 22 $89,453
Spiriva Respimat Tiotropium Bromide Brand 115 $68,029
Dupixent Pen Dupilumab Brand 15 $55,424
Advair Hfa Fluticasone Propion/Salmeterol Brand 53 $23,691
Epinephrine Generic 99 $23,227
Breo Ellipta Fluticasone/Vilanterol Brand 48 $22,938
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 147 $22,059
Symbicort Budesonide/Formoterol Fumarate Brand 80 $21,243
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 20 $18,591

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$549,707

Of which drugs: $339,070

Medicare patients

524

Average age 72

Services billed

42,051

347 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 28%
Ischemic heart disease 24%
COPD 23%
Depression 23%
Chronic kidney disease 18%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $21,508
  • Regeneron Healthcare Solutions, Inc. $7,460
$28,968 37 —
NUCALA
  • GlaxoSmithKline, LLC. $9,686
$9,686 — —
Xolair
  • Genentech USA, Inc. $163
$163 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $94
  • Amgen Inc. $68
$162 — —
AREXVY
  • GlaxoSmithKline, LLC. $127
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

461 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record